Delcath Systems, Inc. (DCTH): Price and Financial Metrics
GET POWR RATINGS... FREE!
DCTH POWR Grades
- Sentiment is the dimension where DCTH ranks best; there it ranks ahead of 56.19% of US stocks.
- DCTH's strongest trending metric is Momentum; it's been moving down over the last 48 weeks.
- DCTH's current lowest rank is in the Quality metric (where it is better than 7.69% of US stocks).
DCTH Stock Summary
- DCTH's price/sales ratio is 37.77; that's higher than the P/S ratio of 93.58% of US stocks.
- Over the past twelve months, DCTH has reported earnings growth of 293.08%, putting it ahead of 91.8% of US stocks in our set.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for DCTH comes in at -35.59% -- higher than that of only 7.94% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Delcath Systems Inc, a group of peers worth examining would be HTBX, PI, CRNC, WATT, and EH.
- Visit DCTH's SEC page to see the company's official filings. To visit the company's web site, go to delcath.com.
DCTH Valuation Summary
- In comparison to the median Healthcare stock, DCTH's price/sales ratio is 241.85% higher, now standing at 38.8.
- DCTH's price/sales ratio has moved up 37.8 over the prior 40 months.
- DCTH's price/sales ratio has moved up 37.8 over the prior 40 months.
Below are key valuation metrics over time for DCTH.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| DCTH | 2021-08-31 | 38.8 | 4.9 | -2.9 | -2.3 |
| DCTH | 2021-08-30 | 35.2 | 4.4 | -2.6 | -2.0 |
| DCTH | 2021-08-27 | 35.8 | 4.5 | -2.7 | -2.0 |
| DCTH | 2021-08-26 | 35.7 | 4.5 | -2.7 | -2.0 |
| DCTH | 2021-08-25 | 36.2 | 4.5 | -2.7 | -2.1 |
| DCTH | 2021-08-24 | 34.7 | 4.3 | -2.6 | -2.0 |
DCTH's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- DCTH has a Quality Grade of D, ranking ahead of 7.69% of graded US stocks.
- DCTH's asset turnover comes in at 0.07 -- ranking 158th of 183 Medical Equipment stocks.
- 500 - Internal server error
The table below shows DCTH's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.070 | 0.627 | 39.890 |
| 2021-03-31 | 0.067 | 0.613 | 14.650 |
| 2020-12-31 | 0.081 | 0.611 | 9.684 |
| 2020-09-30 | 0.109 | 0.569 | 1.033 |
| 2020-06-30 | 0.099 | 0.556 | 0.617 |
| 2020-03-31 | 0.132 | 0.563 | 0.458 |
DCTH Price Target
For more insight on analysts targets of DCTH, see our DCTH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $22.75 | Average Broker Recommendation | 1.25 (Strong Buy) |
DCTH Stock Price Chart Interactive Chart >
DCTH Price/Volume Stats
| Current price | $10.50 | 52-week high | $25.18 |
| Prev. close | $10.40 | 52-week low | $8.28 |
| Day low | $10.23 | Volume | 7,538 |
| Day high | $10.50 | Avg. volume | 137,110 |
| 50-day MA | $9.59 | Dividend yield | N/A |
| 200-day MA | $13.46 | Market Cap | 77.24M |
Delcath Systems, Inc. (DCTH) Company Bio
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's lead product candidate is the melphalan hydrochloride for injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. Its Phase III clinical trial products include FOCUS Trial for the patients with hepatic dominant ocular melanoma; and ALIGN Trial for intrahepatic cholangiocarcinoma. The company also offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.
Latest DCTH News From Around the Web
Below are the latest news stories about Delcath Systems Inc that investors may wish to consider to help them evaluate DCTH as an investment opportunity.
Delcath Systems Announces Second Quarter 2021 ResultsNEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today reported business highlights and financial results for the second quarter ended June 30, 2021. |
Delcath Systems Secures Up to a $20.0 Million Debt Facility with Avenue Venture Opportunities Fund, L.P.NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that it has entered into a debt facility with Avenue Venture Opportunities Fund, L.P. ("Avenue Venture Fund") providing up to $20 million with an initial $15 million funded at close. Additional details concerning the debt facility will be contained in the company''s Current Report on Form 8-K to be filed shortly with the Securities and Exchange Commission. |
Delcath Systems to Present at Upcoming Virtual Investor ConferencesNEW YORK, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will participate in two upcoming conferences: |
Will Delcath Systems, Inc. (DCTH) Report Negative Earnings Next Week? What You Should KnowDelcath Systems, Inc. (DCTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Delcath Systems Schedules Conference Call to Report 2021 Second Quarter Financial ResultsNEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on August 10, 2021 at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2021. |
DCTH Price Returns
| 1-mo | 13.64% |
| 3-mo | -16.73% |
| 6-mo | -14.29% |
| 1-year | -2.51% |
| 3-year | -99.18% |
| 5-year | -100.00% |
| YTD | -41.41% |
| 2020 | -15.67% |
| 2019 | -89.16% |
| 2018 | -99.39% |
| 2017 | -99.97% |
| 2016 | -88.50% |
Loading social stream, please wait...